{"id":70723,"date":"2026-05-12T09:57:27","date_gmt":"2026-05-12T09:57:27","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70723"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"kisspeptin-10","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/kisspeptin-10\/","title":{"rendered":"Kisspeptina-10"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta Rapida \u2014 Cos'\u00e8 il Kisspeptin-10?<\/h3>\n<p style=\"margin: 0;\"><strong>Kisspeptina-10<\/strong> (KP-10) is a 10-amino-acid C-terminally amidated peptide and the most-studied active fragment of the KISS1 gene product. It is the apical endogenous regulator of GnRH neuronal activity \u2014 published studies established it as the upstream switch that initiates puberty and drives pulsatile gonadotropin release. Acts via the GPR54 (KISS1R) G-protein-coupled receptor. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">374675-21-5 (kisspeptin-10, umano)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formula Molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1302.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH<sub>2<\/sub> (YNWNSFGLRF-NH<sub>2<\/sub>, 10 amminoacidi; frammento attivo amidato C-terminalmente del kisspeptin maturo di 54 aa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvere liofilizzata (da bianca a biancastra)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificato con HPLC, COA disponibile su richiesta)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C (frigorifero) per lo stock di lavoro; \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Ricostituito: 2\u20138 \u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. Non congelare e scongelare la soluzione ricostituita.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Acqua batteriostatica (consigliata) o acqua sterile per finestre d'uso pi\u00f9 brevi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 il Kisspeptin-10?<\/h2>\n<p><strong>Kisspeptina-10<\/strong> (KP-10) is a 10-amino-acid peptide and the most extensively studied active fragment of the KISS1 gene product, a 145-amino-acid preprokisspeptin that is processed into the 54-amino-acid mature kisspeptin and several shorter C-terminal active fragments (kisspeptin-14, kisspeptin-13, kisspeptin-10). All of the shorter fragments share the C-terminal 10-residue active core and have comparable potency at the kisspeptin receptor \u2014 kisspeptin-10 is the shortest fully active form and is by far the most common peptide in the kisspeptin literature. The well-characterised sequence is YNWNSFGLRF-NH<sub>2<\/sub>, peso molecolare 1302.45 Da, formula empirica C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub>. L'amidazione C-terminale \u00e8 essenziale per la piena attivit\u00e0 del recettore. KISS1 \u00e8 stato originariamente identificato come un gene soppressore di metastasi da Lee et al. (Cancer Res 1996) ed \u00e8 stato rinominato kisspeptin in onore di Hershey, Pennsylvania (casa dei cioccolatini Hershey\u2019s Kisses) dove il gene \u00e8 stato clonato per la prima volta. Il ruolo riproduttivo \u2014 KISS1\/GPR54 come regolatore apicale dei neuroni GnRH e il guardiano molecolare della pubert\u00e0 \u2014 \u00e8 stato stabilito da due articoli indipendenti nel 2003 (Seminara et al., NEJM; de Roux et al., PNAS) dimostrando che mutazioni con perdita di funzione di GPR54 causano ipogonadismo ipogonadotropo idiopatico negli esseri umani. Il kisspeptin-10 \u00e8 fornito come polvere liofilizzata ad alta purezza per ricostituzione con acqua batteriostatica. Esso \u00e8 <strong>dalla FDA, EMA, MHRA o da qualsiasi altro importante regolatore per uso terapeutico umano. Il DSIP di grado di ricerca venduto qui \u00e8 fornito<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use, although ongoing IVF and infertility is investigating clinical applications. <\/p>\n<h2>Meccanismo d'Azione \u2014 Segnalazione GPR54 \/ KISS1R e l'Asse HPG<\/h2>\n<p>What makes kisspeptin-10 mechanistically distinctive among reproductive-peptides is its position as the <strong>regolatore apicale a monte<\/strong> of the entire hypothalamic-pituitary-gonadal (HPG) axis. The peptide acts at a single receptor \u2014 GPR54 (also called KISS1R) \u2014 but the downstream cascade controls the full reproductive endocrine system in published studies:<\/p>\n<ul>\n<li><strong>Attivazione di GPR54 (KISS1R) sui neuroni GnRH<\/strong> \u2014 Il kisspeptin-10 si lega a GPR54, un recettore accoppiato a proteine G di classe A espresso densamente sui corpi cellulari dei neuroni GnRH nei nuclei arcuati ipotalamici e periventricolari anteroventrali. L'attivazione del recettore si accoppia a G\u03b1<sub>q\/11<\/sub> e alla fosfolipasi C, aumentando il calcio intracellulare e innescando la depolarizzazione dei neuroni GnRH e il rilascio pulsatile di GnRH nel sistema portale ipofisario. Questo \u00e8 il meccanismo pi\u00f9 diretto \u2014 la scarica dei neuroni GnRH \u00e8 il passaggio limitante dell'attivit\u00e0 dell'asse HPG, e il kisspeptin \u00e8 il principale stimolo endogeno.<\/li>\n<li><strong>Regolazione dell'asse HPG in modalit\u00e0 pulsatile vs surge<\/strong> \u2014 Kisspeptin neurons in the arcuate nucleus drive the pulsatile GnRH\/LH pattern that maintains gonadal function throughout adult reproductive life. A separate population of kisspeptin neurons in the anteroventral periventricular nucleus (in rodents) generates the preovulatory LH surge in females. Studies using selective stimulation or knockout of these populations has dissected the two modes of HPG-axis output in published studies.<\/li>\n<li><strong>Inizio della pubert\u00e0 e l\u201c\u201dinterruttore kisspeptinico\"<\/strong> \u2014 Loss-of-function GPR54 mutations cause complete failure of puberty onset in humans and animal models; gain-of-function mutations cause central precocious puberty. The &#8220;kisspeptin switch&#8221; hypothesis \u2014 that puberty is initiated when arcuate kisspeptin neurons reach a critical activity threshold \u2014 is the dominant model of pubertal onset in current reproductive neuroscience studies.<\/li>\n<\/ul>\n<p>Kisspeptin-10 has a relatively short plasma half-life (~5\u201310 minutes) due to rapid proteolytic cleavage, particularly at the central RF amide motif by matrix metalloproteinases. Subcutaneous, intravenous, and intracerebroventricular routes are all documented in published studies; the central route is reserved for mechanism-of-action studies in rodents where the BBB-crossing question is relevant. For systemic HPG-axis studies, peripheral administration produces measurable GnRH\/LH responses within minutes of bolus injection. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Kisspeptin-10 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Endocrinologia riproduttiva e farmacologia dell'asse HPG<\/strong> \u2014 dinamiche pulsatile di GnRH\/LH\/FSH, regolazione del feedback gonadico, feedback degli steroidi sessuali sull'attivit\u00e0 dei neuroni kisspeptinici (Seminara et al., NEJM 2003; de Roux et al., PNAS 2003)<\/li>\n<li><strong>Puberty studies<\/strong> \u2014 tempistica dell'inizio puberale nei modelli murini, pattern di attivazione dei neuroni kisspeptinici durante la transizione puberale, analisi meccanicistica della pubert\u00e0 precoce centrale<\/li>\n<li><strong>Hypogonadotropic hypogonadism studies<\/strong> \u2014 preclinical models of GPR54 loss-of-function, kisspeptin-replacement protocols, mechanism-of-action studies for novel hypogonadism therapies<\/li>\n<li><strong>IVF and ovulation induction studies<\/strong> \u2014 alternatives to hCG trigger in IVF protocols, comparative LH-surge induction; clinical translation has reached Phase 2 in some studies programmes although kisspeptin-10 itself is not approved<\/li>\n<li><strong>Polycystic ovary syndrome (PCOS) studies<\/strong> \u2014 altered kisspeptin tone in PCOS preclinical models, LH-pulse frequency abnormalities, follicular maturation studies<\/li>\n<li><strong>Soppressione delle metastasi e biologia del cancro<\/strong> \u2014 KISS1 was originally identified as a metastasis-suppressor gene; published studies continues to investigate kisspeptin&#8217;s anti-metastatic activity in breast, melanoma, and pancreatic cancer models<\/li>\n<li><strong>Cardiovascular and metabolic support<\/strong> \u2014 emergente espressione di KISS1R sui cardiomiociti e sulle cellule \u03b2 pancreatiche; effetti sull'omeostasi del glucosio e sulla contrattilit\u00e0 cardiaca in fase di studio<\/li>\n<li><strong>Comparative reproductive peptide studies<\/strong> \u2014 benchmarking rispetto a <a href=\"https:\/\/medsbase.com\/it\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin-axis sexual-behaviour studies and against <a href=\"https:\/\/medsbase.com\/it\/oxytocin-acetate\/\">Ossitocina Acetato<\/a> per endpoint di affiliazione e legame sociale.<\/li>\n<\/ul>\n<p>Per un contesto pi\u00f9 ampio su dove si colloca la kisspeptina-10 nel panorama dei peptidi riproduttivi e attivi a livello del SNC, vedere <a href=\"https:\/\/medsbase.com\/it\/pt-141\/\">PT-141<\/a> (melanocortin agonist for sexual behaviour studies), <a href=\"https:\/\/medsbase.com\/it\/oxytocin-acetate\/\">Ossitocina Acetato<\/a> (neuropeptide del comportamento affiliativo), e <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> (GHRH-axis hypothalamic-pituitary studies). Browse the full <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">catalogo peptidi<\/a> per composti correlati. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks Kisspeptin-10 in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, HPG-axis pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolli a ciclo esteso, studi su pi\u00f9 coorti, costo per mg pi\u00f9 basso<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because kisspeptin-10 dose ranges are in the low-microgram regime per administration, a single 5\u00a0mg vial supports many weeks of pulse-protocol use at typical doses. <\/p>\n<h2>Confronto \u2014 Kisspeptin-10 vs PT-141<\/h2>\n<p>Kisspeptin-10 e <a href=\"https:\/\/medsbase.com\/it\/pt-141\/\">PT-141 (Bremelanotide)<\/a> are both small CNS-active peptides used in reproductive- and sexual-behaviour studies, but they act on fundamentally different pathways. Kisspeptin-10 acts on the endocrine HPG axis at the GnRH-neuron level; PT-141 acts on the melanocortin behavioural-sexual axis at the MC4R level. The two are mechanistically complementary rather than competing in study models. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kisspeptina-10<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">PT-141 (Bremelanotide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Lunghezza<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 aminoacidi (decapeptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">7 aminoacidi (eptapeptide ciclico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Recettore primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GPR54 \/ KISS1R<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Recettori melanocortinici MC3R \/ MC4R<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effetto primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Rilascio di GnRH\/LH\/FSH (endocrino)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Comportamento sessuale mediato dal SNC (comportamentale)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Studies domain<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Asse HPG, pubert\u00e0, ipogonadismo, IVF<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Desiderio sessuale, eccitazione, funzione erettile<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5\u201310 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 ore (SC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso clinico approvato<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None (Phase 2 in IVF studies)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FDA-approved as Vyleesi for HSDD (different molecule from pharmaceutical-grade)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013200 mcg, bolo o impulso<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0.25\u20132 mg, somministrazione singola<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides address different layers of reproductive biology \u2014 kisspeptin-10 the endocrine HPG axis, PT-141 the CNS-mediated behavioural axis \u2014 so they are not direct alternatives. Studies interested in pulsatile GnRH\/LH dynamics, puberty timing, or hypogonadism uses kisspeptin-10. Studies interested in CNS-mediated sexual-arousal pathways uses PT-141. <\/p>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per lo stock di lavoro a breve termine. Per lo stoccaggio a lungo termine non aperto, congelare a \u221220 \u00b0C. Il kisspeptin-10 liofilizzato \u00e8 stabile sotto refrigerazione fino a 24 mesi e a \u221220 \u00b0C fino a 36 mesi. Evitare cicli di congelamento-scongelamento sulla polvere liofilizzata. <strong>Procedura di ricostituzione:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose. For lower-dose work, further dilution into bacteriostatic water (with optional BSA carrier protein at 0.1%) can be used. Swirl gently \u2014 do <strong>not<\/strong> scuotere \u2014 e attendere 2\u20135 minuti per la completa dissoluzione. Una soluzione ricostituita correttamente dovrebbe essere chiara e incolore. <strong>Dopo la ricostituzione:<\/strong> conservare refrigerato a 2\u20138 \u00b0C e utilizzare entro 30 giorni per una stabilit\u00e0 ottimale. Non congelare la soluzione ricostituita \u2014 i cicli di congelamento-scongelamento degradano l'integrit\u00e0 del peptide. Scartare qualsiasi flaconcino che mostri torbidit\u00e0, precipitato o scolorimento. Il kisspeptin-10 \u00e8 suscettibile alla scissione proteolitica al motivo RF-amide C-terminale; la soluzione ricostituita dovrebbe essere utilizzata prontamente entro la finestra di 30 giorni per protocolli che richiedono una calibrazione precisa della dose-risposta. <\/p>\n<h2 id=\"faqs\">Domande frequenti<\/h2>\n<h3>What is Kisspeptin-10 used for in studies?<\/h3>\n<p>Kisspeptin-10 is used in studies investigating the hypothalamic-pituitary-gonadal (HPG) axis, GnRH neuron activity, pulsatile gonadotropin release, puberty onset, hypogonadotropic hypogonadism, polycystic ovary syndrome (PCOS), IVF and ovulation-induction alternatives to hCG, cancer metastasis suppression (KISS1 was originally identified as a metastasis-suppressor gene), and emerging cardiometabolic kisspeptin signalling. It is the canonical tool for KISS1R \/ GPR54 pharmacology. The pharmaceutical-grade kisspeptin-10 sold here is <strong>not<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>In cosa differisce Kisspeptin-10 da PT-141?<\/h3>\n<p>Both are small CNS-active reproductive peptides, but they target different receptors and biological layers. Kisspeptin-10 acts on the GPR54\/KISS1R receptor on GnRH neurons and drives the endocrine HPG axis (LH, FSH, gonadal steroid production). PT-141 acts on MC3R\/MC4R melanocortin receptors in the CNS and drives behavioural-sexual responses (desire, arousal, erectile function). The two are mechanistically complementary and address different studies questions. <\/p>\n<h3>Qual \u00e8 la differenza tra Kisspeptin-10 e Kisspeptin-54?<\/h3>\n<p>Both are active fragments of the KISS1 gene product. Kisspeptin-54 (also called metastin) is the full-length mature 54-amino-acid peptide secreted in vivo. Kisspeptin-10 is the C-terminal 10-amino-acid active core, which retains essentially full receptor potency and is the most commonly used peptide because its smaller size makes synthesis cheaper, purity easier to verify, and reconstitution simpler. Kisspeptin-13 and kisspeptin-14 are intermediate cleavage products that also share the active C-terminal core. All four have comparable potency at GPR54. <\/p>\n<h3>What is the typical Kisspeptin-10 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013200\u00a0mcg per administration in rodent models, given subcutaneously or intravenously for bolus-pulse studies, or as continuous infusion for chronic-stimulation studies. Human IVF has used 6.4\u201312.8\u00a0\u03bcg\/kg as a single subcutaneous trigger dose. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>Kisspeptin-10 \u00e8 approvato dalla FDA?<\/h3>\n<p>No. Kisspeptin-10 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 2 clinical studies in IVF ovulation induction is ongoing, but kisspeptin-10 has not been approved for any clinical indication. <\/p>\n<h3>Come deve essere conservato Kisspeptin-10?<\/h3>\n<p>Flaconcini liofilizzati: refrigerati a 2\u20138 \u00b0C per scorte di lavoro a breve termine, o \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Soluzione ricostituita: refrigerata a 2\u20138 \u00b0C, utilizzare entro 30 giorni. Non congelare la soluzione ricostituita \u2014 i cicli di congelamento-scongelamento degradano il peptide. Proteggere sempre dalla luce diretta. Per diluizioni di lavoro a bassa concentrazione, si consiglia l'uso di proteina carrier BSA (0.1%) per minimizzare le perdite per adsorbimento. <\/p>\n<h3>Come si ricostituisce Kisspeptin-10?<\/h3>\n<p>Seguire la procedura di ricostituzione sopra indicata. Aggiungere acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sulla polvere liofilizzata), agitare delicatamente e attendere 2-5 minuti per la completa dissoluzione. Non <strong>not<\/strong> Agitare la fiala. Una soluzione correttamente ricostituita \u00e8 chiara e incolore. Per una fiala da 5 mg + 2,0 mL di diluente, la concentrazione di lavoro \u00e8 2,5 mg\/mL. <\/p>\n<h3>Quali dosaggi sono disponibili su MedsBase?<\/h3>\n<p>MedsBase carries Kisspeptin-10 in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Perch\u00e9 KISS1 \u00e8 stato originariamente chiamato kisspeptin?<\/h3>\n<p>Il gene KISS1 \u00e8 stato scoperto come gene soppressore di metastasi da Lee et al. a Hershey, Pennsylvania (Cancer Res 1996). Il nome \u201ckisspeptin\u201d era un riferimento scherzoso agli Hershey\u2019s Kisses, il celebre cioccolatino prodotto nella stessa citt\u00e0. Il ruolo riproduttivo \u00e8 stato caratterizzato solo nel 2003 con la pubblicazione simultanea di studi sull'ipogonadismo da mutazione GPR54 umana su NEJM (Seminara et al.) e PNAS (de Roux et al.). Il peptide ha quindi la singolare distinzione di essere stato caratterizzato sia come soppressore di metastasi tumorali che come regolatore apicale della pubert\u00e0 \u2014 due ruoli che rimangono meccanicamente connessi in modo incompleto. <\/p>\n<h3>Does Kisspeptin-10 cause side reported effects?<\/h3>\n<p>Published preclinical and Phase 1\/2 clinical studies has documented good tolerability at typical doses. The predominant on-target effects are HPG-axis activation \u2014 rising LH, FSH, testosterone (males) or estradiol (females), and downstream gonadal steroid effects. Off-target findings include modest cardiovascular effects mediated by KISS1R expression on vascular tissue, and a flushing\/vasodilation effect noted in some human studies at higher doses. Long-term safety data outside contexts is limited. <\/p>\n<h3>Qual \u00e8 l'emivita della Kisspeptina-10?<\/h3>\n<p>In preclinical and clinical studies, kisspeptin-10 has a plasma half-life of approximately 5\u201310 minutes following intravenous or subcutaneous administration. The short half-life is due to rapid proteolytic cleavage by matrix metalloproteinases at the central RF-amide motif. For chronic-stimulation studies, continuous infusion or repeated pulse-dosing protocols are used to maintain receptor occupancy. <\/p>\n<h3>How long does Kisspeptin-10 take to show effects in preclinical studies?<\/h3>\n<p>Acute LH responses to bolus kisspeptin-10 administration are detectable within 5\u201315 minutes in rodent and human studies. FSH and downstream gonadal steroid responses develop over hours to days. Chronic-stimulation effects on puberty timing in young rodent models manifest over the natural pubertal window \u2014 days to weeks depending on species and developmental stage at intervention. <\/p>\n<h3>Posso ordinare la Kisspeptina-10 per la spedizione internazionale?<\/h3>\n<p>S\u00ec. MedsBase spedisce Kisspeptina-10 in tutto il mondo dalla nostra rete dedicata di spedizione di peptidi. Gli ordini contenenti solo peptidi si qualificano per il nostro servizio di spedizione autonomo per peptidi. Tutti gli ordini vengono spediti in imballaggi a temperatura controllata con tracciamento completo e sono coperti dal nostro <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\">Politica di Garanzia di Rispedizione<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Reproductive, CNS, and Behavioural Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Cyclic heptapeptide melanocortin agonist \u2014 CNS-mediated sexual-behaviour studies<\/li>\n<li><a href=\"\/it\/oxytocin-acetate\/\"><strong>Ossitocina Acetato<\/strong><\/a> \u2014 9-aa cyclic neuropeptide \u2014 social-bonding and affiliative behavioural support<\/li>\n<li><a href=\"\/it\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 hypothalamic-pituitary-axis studies<\/li>\n<li><a href=\"\/it\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth-axis studies<\/li>\n<li><a href=\"\/it\/selank\/\"><strong>Selank<\/strong><\/a> \u2014 Anxiolytic heptapeptide \u2014 GABA \/ BDNF stress resilience<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Approfondimenti<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore reproductive and CNS-active peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Sfoglia l'intera <a href=\"https:\/\/medsbase.com\/it\/peptides\/\"><strong>catalogo peptidi<\/strong><\/a>, con composti correlati tra cui <a href=\"https:\/\/medsbase.com\/it\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin sexual-behaviour studies, <a href=\"https:\/\/medsbase.com\/it\/oxytocin-acetate\/\">Ossitocina Acetato<\/a> for affiliative-behaviour studies, and <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> for hypothalamic-pituitary-axis studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Regolatore apicale dell'attivit\u00e0 dei neuroni GnRH<br \/>\n\u2705 Agonista del recettore KISS1R \/ GPR54<br \/>\n\u2705 HPG-axis &amp; puberty compound<br \/>\n\u2705 IVF and ovulation-induction studies<br \/>\n\u2705 Originariamente identificato come soppressore di metastasi<\/p>\n<p><strong>Kisspeptina-10<\/strong> contiene composto peptidico sintetico.<\/p>","protected":false},"featured_media":70963,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6277,5441],"class_list":["post-70723","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-kisspeptin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/70723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=70723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/70963"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=70723"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=70723"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=70723"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=70723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}